Clinical trial · Expanded Access
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)
NCT00872950CI-TRIAL-00057709LEMSapproved for marketingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Congenital Myasthenic Syndrome | — | UNRESOLVED | — |
| Lambert-Eaton Myasthenic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3,4-DIAMINOPYRIDINE | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis * 18 years or older * Females must have negative pregnancy test and be willing to practice an effective form of birth control * No prolonged QT syndrome as indicated by baseline EKG Exclusion Criteria: * Known sensitivity to 3,4-DIAMINOPYRIDINE * History of seizures and/or severe asthma
References
Publications (0)
Data not yet available
No reference posted for this study.